Tempus AI (TEM) Stock Soars 11% on Groundbreaking Cancer AI Study and Quarterly Earnings

Tempus AI (TEM) stock rallied 11% Friday after Nature Medicine validated its PRISM2 cancer AI model, while reporting its first quarterly profit.

The post Tempus AI (TEM) Stock Soars 11% on Groundbreaking Cancer AI Study and Quarterly Earnings appeared first on Blockonomi.